FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965945579> ?p ?o ?g. }

• W1965945579 endingPage "R1380" @default.
• W1965945579 startingPage "R1379" @default.
• W1965945579 abstract "APPETITE, OBESITY, DIGESTION, AND METABOLISMFor the ZDF rat, “Breaking Up Is Hard To Do”: dissociation of the GK:GKRP complexAlex J. LangeAlex J. LangePublished Online:01 Apr 2007https://doi.org/10.1152/ajpregu.00867.2006This is the final version - click for previous versionMoreSectionsPDF (39 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat glucokinase (GK) is the enzyme that converts glucose, a major fuel of the body, into glucose-6-phosphate (G-6-P) in liver, pancreatic beta cells, and some specialized neurons, as well as enteroendocrine and pituitary cells (12). G-6-P is the gateway to the major pathways of glucose utilization: glycolysis, the oxidation of glucose, the pentose phosphate pathway, and glycogenesis. GK performs different functions in the tissues where it is expressed. In liver, in the postprandial state when insulin is elevated, GK increases glucose utilization as part of decreasing net hepatic glucose output (HGO) to prevent the liver from contributing to hyperglycemia. In pancreatic beta cells, GK is thought to act as a glucose sensor leading to the release of insulin in the well-established cascade of events, glucose uptake via the transporter GLUT2, phosphorylation by GK, increased the ATP-to-ADP ratio, closing of K+-gated channels, membrane depolarization, and Ca2+ influx leading to secretion of insulin (13). Recently, GK has been shown to play a role in glucose sensing in the ventral medial hypothalamus, which is involved in regulation of the glucose homeostasis. Experimentally decreasing (siRNA) or increasing (activator) GK had the expected effects on Ca2+ oscillations in glucose-excitatory and glucose-inhibitory neurons (10).Classically, the control of glycolysis was thought to be at the phosphofructokinase-1 (PFK1) reaction, which was considered the rate-limiting step in the pathway, by crossover experiments (5). The major role that GK plays in the control of pathway flux was elucidated by metabolic control analysis (8), where GK was shown to have a much higher flux control coefficient than PFK1 on the process of glycolysis in liver. This analysis established the shared roles of enzymes in a given pathway and revealed that GK contributed a lion's share to the control of glycolysis and glycogenesis (7). This is still a simplification, although it is quantitative. The physiologic key is that GK is a high Km (actually, the half-saturation constant S0.5) hexokinase, equal to the normal blood glucose concentration (5–8 mM), and therefore can respond to changes in blood glucose in the physiological range. GK, although monomeric, displays sigmoidal kinetics, with the inflection point at normal physiological concentrations of glucose. In an elegant structural study, Kamata, et al., (9) show that GK exists in three conformational states and has two catalytic cycles. Both the closed and open forms are active and the super-open form is inactive. GK enters into a fast (open-to-closed) or slow (super-open to open-to-closed) catalytic cycle depending on the concentration of glucose; at high glucose the enzyme goes into the fast cycle and at low glucose into the slow cycle, explaining the low affinity and sigmoidal saturation curve of the enzyme.GK has major roles in pancreatic beta cells and liver in the control of blood glucose homeostasis. Mutations in GK lead to maturity-onset diabetes in the young (type 2 diabetes; T2D). Over 100 mutations that compromise some aspect of GK have been characterized (12). Several mutations have also been identified that lead to higher-than-normal GK activity, which leads to hypoglycemia (12). For these reasons, GK is a strong target for the pharmacological treatment of T2D. Small molecular weight GK activators (GKAs) that bind to GK and activate it are currently being developed as antidiabetic drugs (2, 4, 6). These GKAs, some currently in clinical trials, have great potential to reduce hyperglycemia in diabetic patients.In the liver, and most likely in other tissues as well, regulation of GK activity goes beyond its kinetic properties. In the liver, GK regulatory protein (GKRP) sequesters GK in the nucleus in an inactive conformation. In response to high glucose, GK dissociates from GKRP and translocates to the cytoplasm where it is active. Low concentrations of sorbitol or fructose, as precursors of fructose-1-phosphate, also dissociate GK from GKRP, leading to translocation out of the nucleus and activation (1, 17).Levels of GK in the nucleus are never depleted, regardless of metabolic state, providing food for thought that GK may have other noncatalytic functions in the nucleus. A proteomic approach to analyzing protein complexes has revealed that GK is also present in a mitochondrial complex containing BAD, a proapoptotic Bcl-2 family member that induces apoptosis by inhibiting the antiapoptotic molecule Bcl-XL. Danial et al (3) suggest that mitochondrial-bound GK performs a key role in apoptosis in response to various factors, such as extrinsic stimuli and metabolic states. Additionally, there are other binding partners that effect the compartmentation and activity of GK. For example, GK forms a complex with the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, where complexed GK activity is increased and GK may be sequestered in the cytosol (11, 14).It has been established that glucose-induced suppression of net HGO is associated with increased glucose phosphorylation and active GK, and that the impaired suppression of net hepatic glucose production and the defective hepatic glucose uptake in response to increased plasma glucose seen in T2D is due to the failure of increased plasma glucose to enhance flux through GK.In this issue of the American Journal of Physiology–Regulatory, Integrative and Comparative Physiology, Shin, et al. (16) report studies on GK in the Zucker diabetic fatty (ZDF) rat, a model that presents strong parallels to humans with T2D. The authors examine the role of hepatic GK on a physiological whole body level. By using clamping and tracer analysis they were able to quantitate glucose turnover, total HGO, hepatic glucose cycling, and incorporation into glycogen and thereby get a comprehensive view of liver carbohydrate metabolism. In this model, they observed that glucose utilization is not increased when blood glucose is increased as it is in normal-weight rats. They demonstrated that this is due to a defect in the glucose-dependent translocation of GK to the cytosol, leaving it sequestered in the nucleus in an inactive state. Therefore, GK is incapable of increasing glucose phosphorylation, and there is no decrease in net HGO. They pinpoint the inability of GK to translocate in response to glucose to the inability of glucose to dissociate GK from the inhibitory grip of GKRP in the nucleus. This is based on the rescue of GK translocation by the addition of sorbitol at low concentration, which dissociates GK from GKRP. Sorbitol restores glucose phosphorylation and decreases net HGO, rescuing the normal hepatic response to glucose. Clearly, these are two distinct mechanisms bringing about the dissociation of GK from GKRP. How they are related and what differentiate them are questions currently under investigation.Several implications can be drawn from the authors' observations. First, these observations demonstrate the importance of liver GK in the maintenance of normal glucose homeostasis. However, because of clamping and tracer methodologies, liver metabolism is experimentally more accessible, and we may not fully appreciate the role of GK in the control of whole body glucose metabolism as guided from glucose-sensitive neurons in the hypothalamic regions of the brain. Second, since this defect was discovered in an early stage of diabetes, it could be a cause of the progression to diabetes seen in the adult ZDF rat. We must remember that the etiology of T2D is complex and likely involves multiple defects that conspire to generate the phenotype. Third, the ZDF rat model may be limited as far as parallels with T2D in humans is concerned. One wonders whether the same dissociation defect is seen in humans with T2D and, furthermore, how this step is affected by GKAs that are in the pharmaceutical pipeline. Will the GKAs be able to overcome the defect?Clearly, basic research on the regulation of GK remains an important area of study. It is important to understand the subtleties that come to bear on the efficacy of antidiabetes therapies utilizing GK as a target.NOTE ADDED IN PROOFWhile this editorial focus was in review, an in-depth review of GK regulation in liver and pancreatic beta cells was published (Baltruch S, Tiedge M. Glucokinase regulatory network in pancreatic beta-cells and liver. Diabetes 55, Suppl 2: S55–S65, 2006).REFERENCES1 Agius L, Stubbs M. Investigation of mechanism by which glucose analogues cause translocation of glucokinase in hepatocytes: evidence for two binding sites. Biochem J 346: 413–421, 2000.Crossref | PubMed | ISI | Google Scholar2 Brocklehurst KJ, Payne VA, Davies RA, Carroll D, Vertigan HL, Wightman HJ, Aiston S, Waddell ID, Leighton B, Coghlan MP, Agius L. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 53: 535–541, 2004.Crossref | PubMed | ISI | Google Scholar3 Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, Gygi SP, Korsmeyer SJ. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952–956, 2003.Crossref | PubMed | ISI | Google Scholar4 Futamura M, Hosaka H, Kadotani A, Shimazaki H, Sasaki K, Ohyama S, Nishimura T, Eiki JI, Nagata Y. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 281: 37668–37674, 2006.Crossref | PubMed | ISI | Google Scholar5 Ghosh AK, Sloviter HA. Glycolysis and the Pasteur effect in rat reticulocytes. J Biol Chem 248: 3035–2040, 1973.PubMed | ISI | Google Scholar6 Grimsby J, Sarabu R, Corbett WL, Haynes N, Bizzaro FT, Coffey JW, Guertin KR, Hillard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370–372, 2003.Crossref | PubMed | ISI | Google Scholar7 Härndahl L, Schmoll D, Herling AW, Agius L. The role of glucose 6-phosphate in mediating the effects of glucokinase overexpression on hepatic glucose metabolism. FEBS J 273: 336–346, 2006.Crossref | PubMed | ISI | Google Scholar8 Kacser H, Porteous W. Control of metabolism: What do we measure? Trends Biochem Sci 12: 7–14, 1987.Google Scholar9 Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12: 429–438, 2004.Crossref | PubMed | ISI | Google Scholar10 Kang L, Dunn-Meynell AA, Routh VH, Gaspers LD, Nagata Y, Nishimura T, Eiki J, Zhang BB, Levin BE. Glucokinase is a critical regulator of ventromedial hypothalamic neuronal glucosensing. Diabetes 55: 412–420, 2006.Crossref | PubMed | ISI | Google Scholar11 Massa L, Baltrusch S, Okar DA, Lange AJ, Lenzen S, Tiedge M. Interaction of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2) with glucokinase activates glucose phosphorylation and glucose metabolism in insulin-producing cells. Diabetes 53: 1020–1029, 2004.Crossref | PubMed | ISI | Google Scholar12 Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, Taub R, Grimsby J. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55: 1–12, 2006.Crossref | PubMed | ISI | Google Scholar13 Newgard CB, McGarry JD. Metabolic coupling factors in pancreatic beta cell signal transduction. Annu Rev Biochem 64: 689–719, 1995.Crossref | PubMed | ISI | Google Scholar14 Payne VA, Arden C, Wu C, Lange AJ, Agius L. Dual role of phosphofructokinase-2/fructose bisphosphatase-2 in regulating the compartmentation and expression of glucokinase in hepatocytes. Diabetes 54: 1949–1957, 2005.Crossref | PubMed | ISI | Google Scholar15 Sedaka N, Greenfield H. “Breaking Up Is Hard To Do.” Recorded by Neil Sedaka, 1962.Google Scholar16 Shin JS, Torres TP, Catlin RL, Donahue EP, Shiota M. A defect in glucose-induced dissociation of glucokinase from the regulatory protein in Zucker diabetic fatty rats in the early stage of diabetes. Am J Physiol Regul Integr Comp Physiol 292: R1381–R1390, 2007.Link | ISI | Google Scholar17 Van Schaftingen E, Veiga-da-Cunha M, and Niculescu L. The regulatory protein glucokinase. Biochem Soc Trans 25: 136–140, 1997.Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: A. J. Lange Dept. of Biochemistry, Molecular Biology, and Biophysics, Univ. of Minnesota Medical School, 321 Church St. SE, 6-155 Jackson Hall, Minneapolis, MN 55455-0826 (e-mail: [email protected]) Download PDF Back to Top Next FiguresReferencesRelatedInformation More from this issue > Volume 292Issue 4April 2007Pages R1379-R1380 Copyright & PermissionsCopyright © 2007 the American Physiological Societyhttps://doi.org/10.1152/ajpregu.00867.2006PubMed17185403History Published online 1 April 2007 Published in print 1 April 2007 Metrics" @default.
• W1965945579 created "2016-06-24" @default.
• W1965945579 creator A5068745563 @default.
• W1965945579 date "2007-04-01" @default.
• W1965945579 modified "2023-09-27" @default.
• W1965945579 title "For the ZDF rat, “Breaking Up Is Hard To Do”: dissociation of the GK:GKRP complex" @default.
• W1965945579 cites W1603094431 @default.
• W1965945579 cites W1662650080 @default.
• W1965945579 cites W2007163482 @default.
• W1965945579 cites W2030618728 @default.
• W1965945579 cites W2037702045 @default.
• W1965945579 cites W2087036494 @default.
• W1965945579 cites W2090632954 @default.
• W1965945579 cites W2091992338 @default.
• W1965945579 cites W2111056062 @default.
• W1965945579 cites W2112040506 @default.
• W1965945579 cites W2114662094 @default.
• W1965945579 cites W2115247153 @default.
• W1965945579 cites W2128698550 @default.
• W1965945579 cites W2164306929 @default.
• W1965945579 cites W2178375292 @default.
• W1965945579 cites W4241819528 @default.
• W1965945579 doi "https://doi.org/10.1152/ajpregu.00867.2006" @default.
• W1965945579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17185403" @default.
• W1965945579 hasPublicationYear "2007" @default.
• W1965945579 type Work @default.
• W1965945579 sameAs 1965945579 @default.
• W1965945579 citedByCount "0" @default.
• W1965945579 crossrefType "journal-article" @default.
• W1965945579 hasAuthorship W1965945579A5068745563 @default.
• W1965945579 hasConcept C102931765 @default.
• W1965945579 hasConcept C147789679 @default.
• W1965945579 hasConcept C185592680 @default.
• W1965945579 hasConcept C192562407 @default.
• W1965945579 hasConceptScore W1965945579C102931765 @default.
• W1965945579 hasConceptScore W1965945579C147789679 @default.
• W1965945579 hasConceptScore W1965945579C185592680 @default.
• W1965945579 hasConceptScore W1965945579C192562407 @default.
• W1965945579 hasIssue "4" @default.
• W1965945579 hasLocation W19659455791 @default.
• W1965945579 hasLocation W19659455792 @default.
• W1965945579 hasOpenAccess W1965945579 @default.
• W1965945579 hasPrimaryLocation W19659455791 @default.
• W1965945579 hasRelatedWork W1975669538 @default.
• W1965945579 hasRelatedWork W1993794261 @default.
• W1965945579 hasRelatedWork W2333767658 @default.
• W1965945579 hasRelatedWork W2408733946 @default.
• W1965945579 hasRelatedWork W2807544101 @default.
• W1965945579 hasRelatedWork W2899084033 @default.
• W1965945579 hasRelatedWork W2950117398 @default.
• W1965945579 hasRelatedWork W2951104772 @default.
• W1965945579 hasRelatedWork W2951559948 @default.
• W1965945579 hasRelatedWork W2951855440 @default.
• W1965945579 hasVolume "292" @default.
• W1965945579 isParatext "false" @default.
• W1965945579 isRetracted "false" @default.
• W1965945579 magId "1965945579" @default.
• W1965945579 workType "article" @default.